New study aims to decode blood cancers with Cutting-Edge technology
NCT ID NCT07445438
First seen Mar 23, 2026 · Last updated Jun 23, 2026 · Updated 10 times
Summary
This study is collecting blood and tissue samples from over 1,000 people with blood cancers like leukemia, lymphoma, and myeloma. Researchers will use advanced genetic and protein analysis to find unique markers (biomarkers) that could help diagnose and treat these diseases more effectively. The goal is to build a national platform to better understand and personalize care for blood cancer patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Parma
RECRUITINGParma, PR, 43126, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this could lead to better ways to diagnose and personalize treatment for blood cancers by identifying unique biomarkers.
What could go wrong
This is an early-stage observational study, not a treatment trial. It may not directly benefit participants, and findings may not translate into clinical practice.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.